These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 74127)

  • 1. [Possibilities for the clinical use of 5-azacytidine].
    Veselý J; Cihák A
    Vopr Onkol; 1977; 23(10):65-73. PubMed ID: 74127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanism of cystostatic effect of 5-azacytidine and its usefulness in clinic].
    Veselý J; Cihák A
    Cas Lek Cesk; 1975 May; 114(20):607-11. PubMed ID: 48423
    [No Abstract]   [Full Text] [Related]  

  • 3. 5-azacytidine.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1981 May; 26():37-46. PubMed ID: 6168559
    [No Abstract]   [Full Text] [Related]  

  • 4. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
    Von Hoff DD; Slavik M; Muggia FM
    Ann Intern Med; 1976 Aug; 85(2):237-45. PubMed ID: 60073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
    McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
    Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
    [No Abstract]   [Full Text] [Related]  

  • 6. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 8. Observations on toxicity and clinical trials with daunomycin.
    Serpick AA; Henderson ES
    Pathol Biol; 1967 Oct; 15(19):909-12. PubMed ID: 4967536
    [No Abstract]   [Full Text] [Related]  

  • 9. Karyotypes of the 5-azacytidine-sensitive and -resistant line of AKR mouse leukemia.
    Seifertová M
    Neoplasma; 1981; 28(3):317-23. PubMed ID: 6170003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of 5-azacytidine].
    Robak T
    Pol Tyg Lek; 1984 Feb; 39(7):215-8. PubMed ID: 6205386
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical pharmacology of mitoxantrone].
    Robak T; Drzewoski J
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1473-5. PubMed ID: 3913945
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice.
    Neil GL; Moxley TE; Kuentzel SL; Manak RC; Hanka LJ
    Cancer Chemother Rep; 1975; 59(3):459-65. PubMed ID: 54211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening study on Taiwan plants for antitumor activities.
    King ML; Wang CT; Chang CF; Hsu HM; Wang SJ; Hartwell JL; Abbott BJ
    Cancer Chemother Rep 2; 1974 Jul; 4(3):1-96. PubMed ID: 4842546
    [No Abstract]   [Full Text] [Related]  

  • 14. [6-Thioguanine in the chemotherapy of leukemias].
    Zidermane AA
    Vopr Onkol; 1979; 25(1):74-83. PubMed ID: 284664
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo.
    Lu LJ; Randerath K
    Mol Pharmacol; 1984 Nov; 26(3):594-603. PubMed ID: 6208475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
    Heby O; Russell DH
    Cancer Res; 1973 Jan; 33(1):159-65. PubMed ID: 4118428
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
    Masi M; Vivarelli F; Paolucci P; Vecchi V
    Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.